{
  "meta": {
    "title": "48_Osteoporosis_And_Calcium_Metabolism",
    "url": "https://brainandscalpel.vercel.app/48-osteoporosis-and-calcium-metabolism-ac67755f.html",
    "scrapedAt": "2025-11-30T12:34:31.653Z"
  },
  "questions": [
    {
      "text": "Which of the following decreases both serum calcium and phosphate levels?",
      "choices": [
        {
          "id": 1,
          "text": "Vitamin D"
        },
        {
          "id": 2,
          "text": "Parathyroid hormone"
        },
        {
          "id": 3,
          "text": "Calcitonin"
        },
        {
          "id": 4,
          "text": "Vitamin A"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Calcitonin</strong> decreases both serum calcium and phosphate levels.&nbsp;</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/81cacc6be93e4ea4994da307a1fd6057x1280x850.JPEG\" alt=\"Explanation Image\"><hr><h3>Related Pearl: Summary of hormones that regulate Ca2+ levels</h3><table>\n<tbody>\n<tr>\n<td><strong>Features</strong></td>\n<td><strong>Parathyroid hormone</strong></td>\n<td><strong>Calcitonin</strong></td>\n<td><strong>Vitamin D</strong></td>\n</tr>\n<tr>\n<td><strong>Stimulus for secretion</strong></td>\n<td>\n<div><span>&darr; Serum Ca<sup>2+</sup></span></div>\n<div><span>osteoblast</span></div>\n</td>\n<td><span>&uarr; Serum Ca <sup>2+</sup></span></td>\n<td>\n<div><span>&darr; Serum Ca<sup>2+</sup></span></div>\n<div><span>&darr; Serum Phosphate</span></div>\n<div><span>&uarr; PTH</span></div>\n</td>\n</tr>\n<tr>\n<td><span><strong>Effect on bone</strong></span></td>\n<td><span>&uarr; Resorption</span></td>\n<td><span>&darr;&nbsp;Resorption</span></td>\n<td>\n<div><span>&darr; Resorption </span></div>\n<div><span>(adequate calcium supply)</span></div>\n<div><span>&uarr; Resorption </span></div>\n<div><span>(inadequate calcium supply)</span></div>\n</td>\n</tr>\n<tr>\n<td><span><strong>Effect on kidney</strong></span></td>\n<td>\n<div><span>&uarr; Ca<sup>2+&nbsp;</sup>reabsorption</span></div>\n<div><span>&darr; PO<sub>4</sub><sup>3-</sup> reabsorption</span></div>\n</td>\n<td>\n<div><span>&darr; Ca<sup>2+</sup> reabsorption</span></div>\n<div><span>&darr; PO<sub>4</sub><sup>3-</sup> reabsorption</span></div>\n</td>\n<td>\n<div><span>&uarr; Ca<sup>2+</sup> reabsorption</span></div>\n<div><span>&uarr; PO<sub>4</sub><sup>3-</sup> reabsorption</span></div>\n</td>\n</tr>\n<tr>\n<td><span><strong>Effect on intestine</strong></span></td>\n<td>\n<div><span>Indirectly stimulates the conversion of </span></div>\n<div><span>25-OH-D to </span></div>\n<div><span>1,25-(OH)<sub>2</sub>-D</span></div>\n</td>\n<td>&nbsp;</td>\n<td><span>&uarr; Ca <sup>2+ </sup>and PO<sub>4</sub><sup>3-</sup>&nbsp; absorption</span></td>\n</tr>\n<tr>\n<td><span><strong>Serum calcium</strong></span></td>\n<td><span>&uarr;</span></td>\n<td><span>&darr;</span></td>\n<td><span>&uarr;</span></td>\n</tr>\n<tr>\n<td><span><strong>Serum phosphorus</strong></span></td>\n<td><span>&darr;</span></td>\n<td><span>&darr;</span></td>\n<td><span>&uarr;</span></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC3570",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following interferes with the absorption of calcium?<div class='question-desc-html'><ol>\n<li>Glucocorticoids</li>\n<li>Phenytoin</li>\n<li>Tetracycline</li>\n<li>Phytates</li>\n<li>Oxalates</li>\n</ol></div>",
      "choices": [
        {
          "id": 1,
          "text": "1,2 and 3"
        },
        {
          "id": 2,
          "text": "4 and 5"
        },
        {
          "id": 3,
          "text": "1,2,3 and 4"
        },
        {
          "id": 4,
          "text": "1,2,3,4 and 5"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Glucocorticoids, phenytoin, tetracyclines, phytates, </strong>and<strong> oxalates</strong> all interfere with the absorption of calcium.</p>\n<p><strong>Glucocorticoids </strong>and<strong> phenytoin </strong>depress intestinal calcium <strong>transport</strong>&nbsp;whereas, <strong>t</strong><strong>etracyclines</strong>,&nbsp;<strong>p</strong><strong>hytates,</strong> phosphates, and <strong>oxalates</strong>&nbsp;form <strong>insoluble complexes</strong> with calcium and thereby interfere with calcium absorption.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA9981",
      "difficulty": "easy"
    },
    {
      "text": "Following a road traffic accident, a patient underwent transfusion with 5 units of packed red blood cells. Soon after, he developed tetany.  His serum calcium level was 7.5 mg/dl on lab reports. Which of the following is preferred as the treatment of choice for the given condition?",
      "choices": [
        {
          "id": 1,
          "text": "Calcium chloride"
        },
        {
          "id": 2,
          "text": "Calcium gluconate"
        },
        {
          "id": 3,
          "text": "Calcium carbonate"
        },
        {
          "id": 4,
          "text": "Calcium lactate"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>This is a case of <strong>hypocalcemia</strong> following a massive blood transfusion and IV <strong>calcium gluconate</strong> is the preferred treatment.</p>\n<p>The hypocalcemia results from Ca<sup>2+</sup> chelation by <strong>citrate</strong> (added to the blood product as preservative and anticoagulant). <strong>Calcium gluconate</strong> is the preferred over calcium chloride for the <strong>emergency treatment of hypocalcemia</strong> because it is <strong>less irritating</strong> and <strong>better tolerated</strong>.&nbsp;</p>\n<p>However, <strong>calcium chloride</strong> may be preferable to calcium gluconate in the presence of <strong>abnormal liver function</strong>, because decreased citrate metabolism results in a slower release of ionized calcium. It is generally reserved for severe symptomatic hypocalcemia, (&lt;4 mg/dL) and when given, should be administered via a central venous access device to avoid extravasation and tissue necrosis.</p>\n<p>Calcium carbonate and calcium lactate are <strong>oral preparations</strong> of calcium.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA9978",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following is true regarding plasma calcium?",
      "choices": [
        {
          "id": 1,
          "text": "Ca2+ sensing receptor is a voltage gated ion channel"
        },
        {
          "id": 2,
          "text": "Albumin bound calcium is physiologically most important"
        },
        {
          "id": 3,
          "text": "Calcium is mainly absorbed from large intestine"
        },
        {
          "id": 4,
          "text": "Acidosis favours ionization of calcium"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Acidosis</strong> favors the <strong>ionization</strong> of calcium.</p>\n<p><strong>Hyperventilation</strong> by causing<strong> alkalosis&nbsp;</strong>favors the deionization of calcium. Alkalosis&nbsp;result in precipitation of tetany and laryngospasm in calcium-deficient patients</p>\n<p>Option A - Ca2+ sensing receptor is a type of <strong>G protein coupled receptor.</strong></p>\n<p>Option B - 50% of the Ca2+ is in <strong>ionized form</strong> and is <strong>physiologically most important.</strong>&nbsp;</p>\n<p>Option C - Calcium is mainly<strong> absorbed</strong> from<strong>&nbsp;</strong>the<strong> small intestine.</strong></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA9976",
      "difficulty": "medium"
    },
    {
      "text": "A 57-year-old post menopausal lady has been on alendronate for the past two years. By which of the following mechanisms does this drug act?",
      "choices": [
        {
          "id": 1,
          "text": "Increasing the osteoid formation"
        },
        {
          "id": 2,
          "text": "Increasing the mineralization of osteoid"
        },
        {
          "id": 3,
          "text": "Decreasing the osteoclast mediated resorption of bone"
        },
        {
          "id": 4,
          "text": "Decreasing the activity of osteoprotegerin"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Alendronate</strong> is a <strong>bisphosphonate</strong> which acts by <strong>decreasing</strong> <strong>osteoclast</strong> mediated bone <strong>resorption.</strong></p>\n<p>Osteoclasts internalize bisphosphonates as they are released along with calcium from the bone surface and then reduce osteoclast activity by:</p>\n<ul>\n<li>Promoting apoptosis of osteoclasts</li>\n<li>Disrupting the cytoskeleton and ruffled border of osteoclasts</li>\n<li>Inhibiting the differentiation of osteoclasts</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA9995",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following is not an indication to use bisphosphonates?",
      "choices": [
        {
          "id": 1,
          "text": "Paget’s disease"
        },
        {
          "id": 2,
          "text": "Vitamin D excess"
        },
        {
          "id": 3,
          "text": "Postmenopausal osteoporosis"
        },
        {
          "id": 4,
          "text": "Hypercalcemia of malignancy"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>Bisphosphonates are <strong>not indicated</strong> in the treatment of vitamin D excess.</p>\n<p>Indications for the use of bisphosphonates:</p>\n<ul>\n<li>Osteoporosis</li>\n<li>Paget&rsquo;s disease</li>\n<li>Hypercalcemia of malignancy</li>\n<li>Osteolytic bone metastasis</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB0002",
      "difficulty": "medium"
    },
    {
      "text": "A 65-year-old lady has been taking zoledronate for the treatment of osteoporosis. She is at a high risk of developing which of the following side effects?",
      "choices": [
        {
          "id": 1,
          "text": "Acute renal failure"
        },
        {
          "id": 2,
          "text": "Ventricular fibrillation"
        },
        {
          "id": 3,
          "text": "Peptic ulcer"
        },
        {
          "id": 4,
          "text": "Anterior uveitis"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Zoledronate </strong>use has been associated with<span> </span><span><strong>acute renal failure.</strong></span></p>\n<p>It is nephrotoxic. So baseline renal function and monitoring of renal function during therapy with zoledronate is recommended.</p>\n<p>Long term complications seen with bisphosphonate therapy are <strong>osteonecrosis of jaw</strong> and <strong>subtrochanteric fracture</strong> of femur.</p><p>The 2024 World Osteoporosis Day campaign, marked on October 20th under the theme <strong>\"Say No to Fragile Bones\"</strong> urges people of all ages to take action in protecting their bone health. It highlights three key points: bone health is essential for well-being and mobility, and preventing osteoporosis requires good nutrition and physical activity. Osteoporosis is a serious threat, and recognizing risk factors, prioritizing early screening, and adhering to treatment can prevent devastating consequences. Finally, bone health must be a healthcare priority, as fragility fractures affect millions annually, requiring investment in post-fracture care to prevent future fractures.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA9999",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is used in the first-line management of postmenopausal osteoporosis?",
      "choices": [
        {
          "id": 1,
          "text": "Estrogen"
        },
        {
          "id": 2,
          "text": "Bisphosphonates"
        },
        {
          "id": 3,
          "text": "Raloxifene"
        },
        {
          "id": 4,
          "text": "Combined oral contraceptives"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Bisphosphonates</strong> are used&nbsp;in the first-line management of <strong>postmenopausal osteoporosis.</strong></p>\n<p>Bisphosphonates are analogs of pyrophosphates. They specifically <strong>inhibit bone resorption</strong> and thus are very effective for the treatment of postmenopausal osteoporosis.</p>\n<p>Bisphosphonates concentrate at sites of active remodeling. They remain in the matrix until the bone is remodeled. Then, they are released in the acid environment of the resorption lacunae and induce apoptosis in osteoclasts.</p>\n<p>Classification of bisphosphonates (mainly based on potency):</p>\n<div class=\"panel-body ng-scope\">\n<p class=\"ng-binding ng-scope\">First-generation:</p>\n<ul>\n<li>Etidronate (least potent)</li>\n<li>Clodronate</li>\n<li>Tiludronate</li>\n</ul>\n<p>Second-generation: 10-100 times more potent than the first generation &nbsp;</p>\n<ul>\n<li>Alendronate</li>\n<li>Pamidronate</li>\n<li>Ibadronate</li>\n</ul>\n<p>Third-generation: 10,000 times more potent than the first generation &nbsp;</p>\n<ul>\n<li>Risedronate</li>\n<li>Zoledronate</li>\n</ul>\n</div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD0781",
      "difficulty": "easy"
    },
    {
      "text": "You start a patient on alendronate for osteoporosis. The patient enquires about the side effects and their management. Which of the following measures would you not recommend to decrease oesophageal irritation?",
      "choices": [
        {
          "id": 1,
          "text": "Remaining upright for 30 minutes"
        },
        {
          "id": 2,
          "text": "Use of proton pump inhibitor at bedtime"
        },
        {
          "id": 3,
          "text": "Shifting to intravenous formulation"
        },
        {
          "id": 4,
          "text": "Administration with food"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>Bisphosphonates are<strong> not recommended</strong> to be <strong>administered</strong>&nbsp;<strong>with&nbsp;food</strong> to minimize esophageal irritation.</p>\n<p>Oral bisphosphonates have <strong>very limited bioavailability </strong>(&lt;1-10%). Bisphosphonates are recommended to be administered after an overnight fast with a full glass of water at least 30 minutes before breakfast.</p>\n<p>Options A and B- Remaining<strong> upright for 30 minutes</strong> after dosing and taking&nbsp;<strong>proton pump inhibitors</strong> at<strong> bedtime</strong> can decrease the symptoms.</p>\n<p>Option C- As esophageal irritation is due to the local direct effect of the oral formulation, shifting to<strong> intravenous formulations</strong> reduces the symptoms.</p>\n<p>Note- The prescribing information of all the oral bisphosphonates states that it has to be taken along with tap or filtered water, and not mineral water as it contains&nbsp;higher amounts of calcium which can interfere with the absorption of bisphosphonates. It is prudent to inform patients to not have the medications with water having higher calcium levels.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA9997",
      "difficulty": "medium"
    },
    {
      "text": "In which of the following conditions is teriparatide indicated?",
      "choices": [
        {
          "id": 1,
          "text": "Severe osteoporosis"
        },
        {
          "id": 2,
          "text": "Paget disease"
        },
        {
          "id": 3,
          "text": "Hypercalcemia"
        },
        {
          "id": 4,
          "text": "Osteosarcoma"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Teriparatide</strong> is indicated in <strong>severe osteoporosis.</strong></p>\n<p>Teriparatide is a recombinant human parathyroid preparation. It<strong> increases bone formation</strong> especially when given in low doses and <strong>intermittently</strong>.</p>\n<p>Although it may be more effective than bisphosphonates and estrogen, it has to be <strong>administered subcutaneously</strong> every day. Hence it indicated mostly in severe osteoporosis.</p>\n<p>Teriparatide increases the risk of <strong>osteosarcoma</strong> and it is contraindicated in conditions that causes high risk of osteosarcoma such as:</p>\n<ul>\n<li><strong>Paget disease</strong></li>\n<li>Prior h/o of radiotherapy</li>\n<li>Young adults with open epiphysis</li>\n<li>Unexplained elevated ALP</li>\n<li><strong>Hypercalcemia</strong></li>\n</ul>\n<p><strong>Abaloparatide</strong> is also a PTHrP preparation available.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA9991",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following drugs promotes bone formation?",
      "choices": [
        {
          "id": 1,
          "text": "Calcitonin"
        },
        {
          "id": 2,
          "text": "Raloxifene"
        },
        {
          "id": 3,
          "text": "Bisphosphonates"
        },
        {
          "id": 4,
          "text": "Teriparatide"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>Teriparatide <strong>increases bone formation</strong> especially when given in low doses and intermittently.<br />Teriparatide is a recombinant preparation of <strong>parathyroid hormone.</strong></p>\n<p>The pharmacologic activity of&nbsp;teriparatide,&nbsp;which is similar to the physiologic activity of PTH, includes stimulating osteoblast function, increasing gastrointestinal calcium absorption, and increasing renal tubular reabsorption of calcium.</p>\n<p>Although it may be more effective than bisphosphonates and estrogen, it has to be&nbsp;<strong>administered subcutaneously</strong>&nbsp;every day. Hence it is indicated mostly in severe osteoporosis.</p>\n<p><strong>Teriparatide</strong> increases the <strong>risk of osteosarcoma</strong> and it is contraindicated in conditions that cause high risk of osteosarcoma such as:</p>\n<ul>\n<li>Paget disease</li>\n<li>Prior h/o of radiotherapy</li>\n<li>Young adults with open epiphysis</li>\n<li>Unexplained elevated ALP</li>\n<li>Hypercalcemia</li>\n</ul>\n<p>Option A:&nbsp;<strong>Calcitonin</strong>&nbsp;decreases bone resorption.</p>\n<p>Option B:<strong>&nbsp;Raloxifene</strong> is a selective estrogen receptor modulator, which decreases bone resorption. It is used to prevent and treat osteoporosis in postmenopausal women.</p>\n<p>Option C:<strong>&nbsp;Bisphosphonates</strong> like alendronate and etidronate decrease bone resorption.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD6610",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following acts by causing both decreased bone resorption and increased bone formation?",
      "choices": [
        {
          "id": 1,
          "text": "Strontium ranelate"
        },
        {
          "id": 2,
          "text": "Ibandronate"
        },
        {
          "id": 3,
          "text": "Teriparatide"
        },
        {
          "id": 4,
          "text": "Calcitonin"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Strontium ranelate </strong>acts by both decreased bone resorption and increased bone formation.</p>\n<p>It is generally reserved for <strong>severe osteoporosis.</strong> Due to an increased incidence of myocardial infarction and other cardiovascular events, the use is restricted in all the approved regions.</p>\n<p>Option B-<strong> Ibandronate</strong>&nbsp;which is a bisphosphonate,&nbsp;<strong>decreases bone resorption only.</strong></p>\n<p>Option C- The pharmacologic activity of teriparatide, which is similar to the physiologic activity of PTH, includes stimulating osteoblast function, increasing gastrointestinal calcium absorption, and increasing renal tubular reabsorption of calcium.</p>\n<p>Option D- Calcitonin also decreases bone resorption.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB0003",
      "difficulty": "easy"
    },
    {
      "text": "A 70-year-old patient with severe backache has a T-score of -3. He is started on a monoclonal antibody against RANKL. Identify the drug.",
      "choices": [
        {
          "id": 1,
          "text": "Romosozumab"
        },
        {
          "id": 2,
          "text": "Denosumab"
        },
        {
          "id": 3,
          "text": "Odanacatib"
        },
        {
          "id": 4,
          "text": "Blosozumab"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The given clinical history depicts a case of <strong>osteoporosis</strong>.&nbsp;<strong>Denosumab</strong> is a<strong> monoclonal </strong>antibody<strong> against RANKL&nbsp;</strong>that is indicated in the treatment of osteoporosis<strong>.</strong></p>\n<p>It inhibits the binding of RANKL to RANK receptors on osteoclasts and thereby inhibiting the activation of osteoclast and also promotes their apoptosis.</p>\n<p>Options A and D:<strong>&nbsp;Romosozumab</strong> and<strong> blosozumab</strong> are monoclonal antibodies<strong> against sclerostin</strong> (sclerostin blocks osteoblast proliferation).</p>\n<p>Option C:<strong>&nbsp;Odanacatib</strong> is an <strong>inhibitor of cathepsin K</strong> which is an enzyme in osteoclast that facilitates bone resorption.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB0004",
      "difficulty": "easy"
    },
    {
      "text": "A post-menopausal lady who is taking estrogen as part of her hormone replacement therapy reads about raloxifene on the internet and wants to change her current treatment. Which of the following is not an advantage of using raloxifene over estrogen?",
      "choices": [
        {
          "id": 1,
          "text": "Reduces fracture rates"
        },
        {
          "id": 2,
          "text": "Avoids endometrial hyperplasia"
        },
        {
          "id": 3,
          "text": "Reduces incidence of venous thrombosis"
        },
        {
          "id": 4,
          "text": "No increase in incidence of breast carcinoma"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<div class=\"page\" title=\"Page 818\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Raloxifene causes a <strong>3-fold increase in deep vein thrombosis</strong> and pulmonary embolism.</p>\n<p>It is a selective estrogen receptor modulator&nbsp;<strong>(SERM)</strong> with the following actions:</p>\n</div>\n</div>\n</div>\n</div>\n<ul>\n<li><strong>Agonist </strong>actions<strong>:</strong>\n<ul>\n<li>Bone - increases bone mineral density and reduces the risk of vertebral fracture</li>\n<li>Lipids - increases the risk of deep vein thrombosis and pulmonary embolism.</li>\n</ul>\n</li>\n<li><strong>Antagonist </strong>actions<strong>:</strong>\n<ul>\n<li>Breast - incidence of breast carcinoma is reduced&nbsp;</li>\n<li>Uterus - endometrial hyperplasia is avoided</li>\n</ul>\n</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB0007",
      "difficulty": "medium"
    },
    {
      "text": "A 45-year-old patient with chronic kidney disease developed secondary hyperparathyroidism for which he was treated appropriately, and was started on cinacalcet. Which of the following best describes the mechanism of action of this drug?",
      "choices": [
        {
          "id": 1,
          "text": "Calcitonin preparation"
        },
        {
          "id": 2,
          "text": "PTH preparation"
        },
        {
          "id": 3,
          "text": "Calcimimetic"
        },
        {
          "id": 4,
          "text": "Vitamin D3 analog"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>Cinacalcet is a <strong>calcimimetic</strong> agent.</p>\n<p>It <strong>activates</strong> the calcium-sensing receptor <strong>(CaSR)</strong> in the parathyroids and blocks PTH secretion.</p>\n<p>Cinacalcet is a <strong>type II calcimimetic agent</strong> , it means that it needs either Ca<sup>2+</sup> or some other agonist to activate CaSR.</p>\n<p>It is indicated for <strong>secondary hyperparathyroidism</strong> due to chronic kidney disease and tumor of parathyroid gland.</p>\n<p>Type I calcimimetic agents are those which can activate CaSR directly such as aminoglycoside and polylysine.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB0010",
      "difficulty": "medium"
    },
    {
      "text": "A 40-year-old male patient who requires weekly hemodialysis is started on sevelamer. Which of the following best describes the mechanism of action of this drug?",
      "choices": [
        {
          "id": 1,
          "text": "Vitamin D analog"
        },
        {
          "id": 2,
          "text": "Calcium-sensing receptor mimetic"
        },
        {
          "id": 3,
          "text": "Phosphate binder"
        },
        {
          "id": 4,
          "text": "Potassium binder"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>Sevelamer is a <strong>phosphate binder</strong> indicated in chronic kidney disease.</p>\n<p>Sevelamer is a<strong> nonabsorbable polymer</strong> that acts as a nonselective anion exchanger that<strong> lowers serum phosphate</strong> concentration.&nbsp;</p>\n<p>It is indicated to lower phosphate levels in patients with<strong> chronic kidney disease</strong> who are on <strong>dialysis.</strong>&nbsp;</p>\n<p>Note: Patiromer is a potassium binder approved for use in hyperkalemia.&nbsp;</p>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC3571",
      "difficulty": "medium"
    }
  ]
}